| __timestamp | Genmab A/S | MiMedx Group, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 79529000 | 90480000 |
| Thursday, January 1, 2015 | 91224000 | 133384000 |
| Friday, January 1, 2016 | 102413000 | 179997000 |
| Sunday, January 1, 2017 | 146987000 | 220119000 |
| Monday, January 1, 2018 | 213695000 | 258528000 |
| Tuesday, January 1, 2019 | 342000000 | 198205000 |
| Wednesday, January 1, 2020 | 661000000 | 181022000 |
| Friday, January 1, 2021 | 1283000000 | 198359000 |
| Saturday, January 1, 2022 | 2676000000 | 208789000 |
| Sunday, January 1, 2023 | 3297000000 | 211124000 |
| Monday, January 1, 2024 | 3790000000 |
Data in motion
In the ever-evolving landscape of corporate finance, understanding operational costs is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Genmab A/S and MiMedx Group, Inc. from 2014 to 2023. Over this period, Genmab A/S has seen a staggering increase in SG&A expenses, growing by over 4,000%, from approximately $80 million in 2014 to nearly $3.3 billion in 2023. This reflects Genmab's aggressive expansion and investment in operational capabilities. In contrast, MiMedx Group, Inc. has maintained a more stable trajectory, with expenses peaking at around $260 million in 2018 and stabilizing around $210 million in recent years. This comparison highlights the diverse strategies companies employ in managing operational costs, offering valuable insights into their financial health and strategic priorities.
Selling, General, and Administrative Costs: Novo Nordisk A/S vs MiMedx Group, Inc.
Zoetis Inc. and Genmab A/S: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of United Therapeutics Corporation and Genmab A/S
Genmab A/S and Incyte Corporation: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of Genmab A/S and Axsome Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Genmab A/S or Cytokinetics, Incorporated
Cost Management Insights: SG&A Expenses for Genmab A/S and Ligand Pharmaceuticals Incorporated
Incyte Corporation and MiMedx Group, Inc.: SG&A Spending Patterns Compared
Jazz Pharmaceuticals plc vs MiMedx Group, Inc.: SG&A Expense Trends
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.
Comparing SG&A Expenses: Alkermes plc vs MiMedx Group, Inc. Trends and Insights
Comparing SG&A Expenses: Verona Pharma plc vs MiMedx Group, Inc. Trends and Insights